ResMed announced a new operating model to accelerate long-term growth, which introduces leadership in product, revenue, and marketing to the global executive team.
The goal of the new operating model is to accelerate profitable growth, while driving greater value and improved care throughout the outside hospital care continuum and the patient journey, according to a release from the company.
“ResMed is the undisputed leader in digital health for respiratory medicine and residential care, and we aspire to make ourselves even more product-led, customer-centric, and brand-enhanced. Today, we are making bold changes to ensure these capabilities are directly represented in our executive leadership team,” says Mick Farrell, ResMed’s CEO, in a release. “We will measure the success of our new operating model through increased product velocity, increased vigilance on long-term profitable revenue delivery, and increased brand engagement with stakeholders.”
ResMed’s new product-led, customer-centric, and brand-enhanced operating model includes the following executive leadership team:
- Leaders appointed into new roles:
- Chief product officer – Justin Leong (previously president, Asia and Latin America)
- Chief marketing officer – Katrin Pucknat (previously president, Germany)
- Chief revenue officer – Mike Fliss (previously vice president, North America sales)
- In addition to the above roles, the executive leadership team also includes:
- Chief commercial officer, SaaS – Bobby Ghoshal
- Chief financial officer – Brett Sandercock
- Chief legal officer – Mike Rider
- Chief people officer – Vered Keisar
- Chief strategy officer – Hemanth Reddy
- The extended CEO operations team, reporting directly to the CEO, includes:
- Chief compliance officer – Jim Ellis
- Chief information security officer – Todd Friedman
- Chief investor relations officer – Amy Wakeham
- Chief medical officer – Carlos Nunez
- Chief quality and regulatory officer – Dawn Haake
- Chief supply chain officer – Andrew Price
ResMed also announced that Rob Douglas, current president and chief operating officer, plans to retire on Jan 1, 2024. Douglas will immediately transition from his current role to a new role as special advisor to the CEO and remain in a consulting role through Dec 31, 2024.
Additionally, Lucile Blaise, current president of sleep and respiratory care, will immediately transition to a new role as senior vice president of strategy and business development, reporting to Hemanth Reddy. Finally, as part of the operating model evolution, the digital health technology product organization will now report to Justin Leong, and Urvashi Tyagi, current chief technology officer, will immediately transition to a role as special advisor to the chief product officer through Jan 1, 2024. Tyagi will remain in a consulting role through Dec 31, 2024.
Photo 141079852 © Hd3dsh | Dreamstime.com
